Latest Headlines

Latest Headlines

Teva snags an EU recommendation for its asthma, COPD inhaler

European regulatory authorities gave Teva a positive opinion for its DuoResp Spiromax inhalation powder, designed to treat asthma and chronic obstructive pulmonary disease. With the recommendation from the Committee for Medicinal Products for Human Use, Teva hopes to have final approval within a few months.

EU Anoro nod lets GSK breathe deeper as Advair faces generic onslaught

While it's still unclear how long copycats will take to make a serious dent in GlaxoSmithKline's respiratory franchise once generic competition inevitably erodes sales of the $8.8 billion-selling Advair, Glaxo may soon have a new building block with European regulators' new recommendation for combo med Anoro.

3M to develop inhaled airway inflammation treatments with Delaware's Invion

3M Drug Delivery Systems has joined forces with the Delaware outfit Invion to develop inhaled drugs for inflammatory airway diseases.

Pulmatrix heralds early stage results for COPD dry powder tech

Massachusetts-based dry-powder specialist Pulmatrix welcomed successful early-stage results for its bronchodilator treatment for chronic obstructive pulmonary disorder, which makes use of its novel lung delivery system iSPERSE.

Boehringer snags EU nods for COPD drug as FDA awaits

Boehringer Ingelheim has won over European regulators with its latest COPD therapy, following a favorable FDA panel vote that set the stage for U.S. approval and entrance into a huge but crowded market.

Novartis COPD drug gets approvals in EU, Japan

Novartis is launching the expected blockbuster into a rapidly expanding but increasingly competitive market as established players and newcomers vie for their piece of the action.

UPDATED: FDA experts endorse new COPD blockbuster from GlaxoSmithKline, Theravance

GlaxoSmithKline and Theravance have nailed down a solid majority of FDA panel votes in favor of marketing their new COPD therapy Anoro Ellipta. The outside experts voted 11 to 2 this afternoon to endorse the therapy, opening the door to the first of several new drug that will likely wind up duking it out in a tough fight for market share.

Crowded field of PhIII COPD contenders will compete for blockbuster market

Over the weekend some of the world's largest drug developers rolled out new data on their late-stage COPD drugs, staying upbeat despite a growing sense among some analysts that many of these new drugs will find it hard to offer much in the way of a significant improvement for patients.

Forest hits setback on new COPD drug, one of its key hopes for sales growth

The delay could interfere with their plans to compete against rival drugs that could get to market first.

3M sells dry powder inhaler rights to Adamis

3M licensed its dry powder drug delivery device for asthma and chronic obstructive pulmonary disease to Adamis for an undisclosed amount, granting the smaller company worldwide rights to bolster its own line of delivery devices.